Effectiveness and Safety of Avatrombopag in Liver Cancer Patients with Severe Thrombocytopenia: Real-World Data and Challenges
Year: 2022
Type: article
Study design: Observational Study
Abstract: Background. Avatrombopag has been approved in patients who have severe thrombocytopenia (<50 × 109/L) and chronic liver disease (CLD) while receiving invasive procedures. The real-world application and effectiveness of avatrombopag in the subgroup patients with liver cancer remain unknown. Methods. Liver cancer patients (including primary liver cancer and colorectal cancer liver metastasis) who had severe thrombocytopenia and received avatrombopag were retrospectively enrolled. Avatrombopag dose, peak and absolute platelet count increase, combination treatment with other thrombopoietic agents, responder (peak count ≥50 × 109/L with absolute increase ≥20 × 109/L) rate, and anticancer treatment effect were analyzed. Thrombosis and bleeding events were assessed. Results. In total, 93 patients were enrolled, with 72 and 21 in the CLD and non-CLD groups, respectively. Patients with CLD had hepatitis B or C, larger spleen volume, and a higher cirrhosis degree. Baseline platelet counts were similar between two groups (median, 37.0 × 109/L vs. 39.0 × 109/L; P = 0.594 ), while patients without CLD had higher peak platelet (median, 134.0 × 109/L vs. 74.0 × 109/L; P = 0.015 ) and absolute increase (median, 101.0 × 109/L vs. 41.0 × 109/L; P = 0.020 ) after avatrombopag treatment. The responder rate was higher in patients without CLD (100% vs. 76.4%; P = 0.010 ). Combined avatrombopag with other thrombopoietic agents significantly increased platelet count; repeated use of avatrombopag produced similar effects with that of initial treatment. Concerning anticancer treatment effect, patients who responded to avatrombopag had a higher disease control rate. No thrombosis or hemorrhagic events were observed, even in patients with portal vein tumor thrombosis. Conclusion. Avatrombopag was safe and effective and ensured successful implementation of anticancer treatment in liver cancer patients with severe thrombocytopenia, accompanied with or without CLD.
Source: Journal of Oncology
DOI: 10.1155/2022/9138195
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,550
Awards: G109427149, G1157524877, G154836866, G1553277705, G1854335863, G2434025611, G2499475934, G2628086415, G2671855597, G2741507781, G2963879242, G3463430239, G3479720840, G3658120538, 基于自噬活性抑制药物在RAS/RAF突变的肝内胆管癌临床 前的探索性研究, 肝细胞癌靶向药物耐药新机制和治疗新策略的研究, G4612496374, G4658579756, G4840911290, G5598408571, G5815185540, G6094866963, G6882099415, G7492070245, G764932746, G7672282188, G7868242258, G8068142209, G841715390, G8464066599, G8495735220, G938782270
OpenAlex ID: W4308624671